Leerink Partners analyst Andrew Berens has maintained their bullish stance on AURA stock, giving a Buy rating yesterday.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Andrew Berens has given his Buy rating due to a combination of factors related to Aura Biosciences Inc’s recent developments and financial standing. The company presented promising data from their Phase 1 trial of bel-sar in non-muscle invasive bladder cancer, showing an increase in complete response rates among high-risk patients. This improvement, alongside consistent results in intermediate-risk patients, indicates potential efficacy of their treatment.
Additionally, Aura Biosciences has outlined a strategic plan for their upcoming Phase 1b/2 trial, which includes innovative approaches such as immune ablation and neoadjuvant treatment. These strategies aim to address the needs of different patient groups and have been discussed with the FDA, suggesting a well-considered path forward. Furthermore, the company’s financial health is robust, with $151 million in cash and cash equivalents, providing a runway into the second half of 2026. These factors combined support the Buy rating, as they reflect both promising clinical progress and financial stability.
According to TipRanks, Berens is an analyst with an average return of -8.4% and a 34.09% success rate. Berens covers the Healthcare sector, focusing on stocks such as AstraZeneca, Incyte, and Arvinas Holding Company.
In another report released yesterday, JMP Securities also reiterated a Buy rating on the stock with a $19.00 price target.